Skip to content
Dx

ICD-10-CM 2027 diagnosis code

C7B.1Secondary Merkel cell carcinoma

✓ Billable / specific

C7B.1 is a valid, billable ICD-10-CM code for secondary merkel cell carcinoma. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.

Code unchanged since ICD-10-CM took effect on October 1, 2015. Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About C7B.1

C7B.1 is the ICD-10-CM diagnosis code for secondary Merkel cell carcinoma. It belongs to category C7B (secondary neuroendocrine tumors), block C7B (secondary neuroendocrine tumors) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within C7B (secondary neuroendocrine tumors), C7B.1 is specifically for secondary Merkel cell carcinoma. Related codes cover secondary carcinoid tumors (C7B.0) and other secondary neuroendocrine tumors (C7B.8).

Use an additional code to identify any functional activity.

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC, relative weight 4.7581), DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC, relative weight 2.3896), DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC, relative weight 1.6955), DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC, relative weight 3.1281), DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC, relative weight 1.4859), DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC, relative weight 1.9453) and 2 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 209.75 (secondary Merkel cell carcinoma).

Coding notes

Applicable toConditions and synonyms classified to this code
  • Merkel cell carcinoma nodal presentation
  • Merkel cell carcinoma visceral metastatic presentation

Notes that apply from higher levels

Instructions written at a parent level also apply to C7B.1.

› From C7B Secondary neuroendocrine tumors
Use additional code
  • code to identify any functional activity

Broader instructions also apply from Chapter 2: Neoplasms.

Alphabetic index entries

4 entries

Terms in the official ICD-10-CM index that lead to C7B.1.

Codes whose notes reference C7B.1

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

ICD-9-CM equivalent

Converter →
  • 209.75Secondary Merkel cell carcinomaapproximate

From the CMS 2018 General Equivalence Mappings (GEMs), the final GEMs release.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2016 (effective 10/1/2015): Added (first year of ICD-10-CM)
  • No changes since FY2016.

Common questions about C7B.1

Is C7B.1 billable?

Yes. C7B.1 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can C7B.1 be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict C7B.1 as a principal diagnosis.

Is C7B.1 a CC or MCC?

No. C7B.1 is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does C7B.1 group to?

C7B.1 is used in the MS-DRG v44.0 logic for MS-DRG 826 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC), MS-DRG 827 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC), MS-DRG 828 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures without CC/MCC), MS-DRG 829 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures with CC/MCC), MS-DRG 830 (Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC), MS-DRG 843 (Other Myeloproliferative Disorders or Poorly Differentiated Neoplastic Diagnoses with MCC) and 2 more. Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.

What is the ICD-9 code for C7B.1?

The CMS General Equivalence Mappings map C7B.1 to ICD-9-CM 209.75.